Jump to content

Vatelizumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Fswitzer4 (talk | contribs) at 15:02, 27 March 2020 (added FDA UNII to drug box). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vatelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetintegrin alpha 2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1]

It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2]

References

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
  2. ^ Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835.